CCRM Enterprises Holdings
661 University Ave., Suite 1002, Toronto, ON, M5G 1M1, Canada
Overview
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting their population, a world-renowned group of stem cell scientists and bioengineers have come together to form CCRM. CCRM’s mission is to generate sustainable health and economic benefits through global collaboration in cell and gene therapy, and regenerative medicine.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 4
Sector focus
- Association
- Biotechnology
- Commercial
- Information Technology
- Non Profit
- Sustainability
Investment portfolio
- Notch Therapeutics
Participated · Series A · Feb 2021
Notch Therapeutics develops homogeneous, universally compatible stem cell–derived T cell and NK cell therapies using its proprietary Engineered Thymic Niche (ETN) platform. The company has built an integrated platform for generating and editing immune cells from clonal induced pluripotent stem cells (iPSCs) and assembled a scientific team to advance multiple T cell therapeutic candidates. Notch has an existing partnership with Allogene Therapeutics to apply the ETN platform to CAR-targeted, off-the-shelf iPSC-derived T cell and NK cell therapies for hematologic cancers. The company intends to use new funding to advance its iPSC-derived T cell portfolio and to achieve clinical readiness for the ETN platform. Notch plans to expand its team to support growth and to establish operations in Seattle in addition to its existing Vancouver and Toronto operations. The technology originated in the laboratories of Juan-Carlos Zúñiga-Pflücker at Sunnybrook Research Institute and Peter Zandstra at the University of Toronto, and the company was incubated with support from MaRS Innovation and the Centre for Commercialization of Regenerative Medicine (CCRM).